Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADALAT vs ELETRIPTAN HYDROBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Acute treatment of migraine with or without aura in adults
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 8 hours. The half-life supports a clinical duration suitable for acute migraine treatment, with no accumulation with single doses.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily metabolized by CYP3A4; also minor contribution from CYP2C9, CYP2C19, and CYP2D6.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Approximately 90% of the dose is eliminated in feces, with less than 10% recovered in urine. Renal excretion accounts for about 9% of total clearance, primarily as unchanged drug. Biliary/fecal elimination is the major route.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Approximately 85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Volume of distribution is approximately 1.4 L/kg (range 1.0-2.0 L/kg), indicating extensive distribution into tissues beyond total body water.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Oral bioavailability is approximately 50% (range 30-70% due to first-pass metabolism) for the tablet formulation. Absolute bioavailability is moderate due to presystemic clearance.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal impairment (Cr Cl <10 m L/min).
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment for mild to moderate impairment.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Not established; safety and efficacy in patients <18 years not studied.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Use with caution due to potential decreased hepatic/renal function; consider lower starting dose (20 mg).
None
No FDA boxed warning.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Coronary artery vasospasm and ischemic heart disease,Cerebrovascular events (stroke, transient ischemic attack),Life-threatening serotonin syndrome (especially with SSRIs/SNRIs),Hypertensive crisis in patients with uncontrolled hypertension,Risk of myocardial ischemia in patients with risk factors
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
History of ischemic heart disease or coronary artery vasospasm,Uncontrolled hypertension,Hemiplegic or basilar migraine,Use within 24 hours of another triptan or ergotamine,Concurrent use of MAO inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment (Child-Pugh C)
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing eletriptan exposure and risk of adverse effects. No other significant food interactions reported.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. Avoid in third trimester due to possible uterine atony or decreased placental perfusion.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Excreted into breast milk in low amounts (M/P ratio unknown). Relative infant dose estimated at <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for irritability and sleep disturbance.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but standard dosing remains safe. Consider lowest effective dose.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Eletriptan has higher lipophilicity and longer half-life than sumatriptan, potentially offering better CNS penetration and sustained efficacy. Contraindicated within 24 hours of other triptans or ergotamines. Avoid in patients with severe hepatic impairment (Child-Pugh C) as metabolism is CYP3A4-dependent. Maximum single dose 40 mg; may repeat after 2 hours if no response, but do not exceed 80 mg/day. Onset typically within 30 minutes; if first dose fails, consider alternative therapy for subsequent attacks.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
Take at the first sign of migraine headache, not for prevention.,Do not take more than 80 mg in 24 hours; wait at least 2 hours between doses.,Avoid taking within 24 hours of other triptans or ergotamine medications.,Report chest pain, palpitations, or shortness of breath immediately.,Do not use if you have uncontrolled high blood pressure, coronary artery disease, or history of stroke.,Grapefruit juice may increase drug levels; avoid consumption during treatment.,Swallow tablet whole; do not crush or chew.
No interactions on record
"Eletriptan, a 5-HT1B/1D receptor agonist used for migraine, and ondansetron, a 5-HT3 receptor antagonist antiemetic, both increase serotonergic activity via different mechanisms. Concurrent use may lead to excessive serotonin accumulation, potentially triggering serotonin syndrome, characterized by neuromuscular excitation, autonomic instability, and altered mental status. While the interaction is mechanistically plausible, clinical reports are rare, and caution is advised particularly in patients on multiple serotonergic agents."
"Concomitant use of eletriptan, a 5-HT1B/1D receptor agonist, with maprotiline, a tetracyclic antidepressant that inhibits serotonin reuptake, may result in additive serotonergic effects. This increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients combining these agents require close monitoring for symptoms such as hyperthermia, clonus, hyperreflexia, and agitation."
"Concomitant use of eletriptan and almotriptan, both triptan-class 5-HT1B/1D receptor agonists, increases the risk of serotonin syndrome and additive vasoconstriction, including coronary vasospasm. Excessive serotonergic activity may lead to neuromuscular excitation, autonomic instability, and altered mental status, while additive arterial vasoconstriction can precipitate severe hypertension or ischemic events, especially in patients with cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADALAT vs ELETRIPTAN HYDROBROMIDE, answered by our medical review team.
ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. ELETRIPTAN HYDROBROMIDE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADALAT and ELETRIPTAN HYDROBROMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. The standard adult dose of ELETRIPTAN HYDROBROMIDE is: 40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADALAT and ELETRIPTAN HYDROBROMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. ELETRIPTAN HYDROBROMIDE is classified as Category D/X. Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. A. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.